Author:
Torrisi R,Bagnardi V,Cardillo A,Bertolini F,Scarano E,Orlando L,Mancuso P,Luini A,Calleri A,Viale G,Goldhirsch A,Colleoni M
Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Banerjee S, Dowsettt M, Ashworth A, Martin L-A (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract 4: 536–550
2. Banerjee S, Pancholi S, A’Hern R, Ghazoui Z, Smith IE, Dowsett M, Martin L-A (2008) The effects of neoadjuvant anastrozole and tamoxifene on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer. Clin Cancer Res 14: 2656–2663
3. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS (2003) Maximum tolerable dose and low-dose metronomic therapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 53: 4342–4346
4. Bertolini F, Shaked Y, Mancuso P, Kerbel RS (2006) The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 6: 835–845
5. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, Aguggini S, Bolsi G, Bonardi S, Tondelli B, Vana F, Tampellini M, Alquanti P, Dogliotti L (2005) Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer 12: 383–392
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献